Morphosys ends development of dermatitis treatment, shares fall [Reuters (UK)]
MorphoSys AG - American Depositary Shares (MOR)
Company Research
Source: Reuters
Morphosys ends development of dermatitis treatment, shares fall - Reuters 1 Min Read BERLIN (Reuters) - A development program for an atopic dermatitis treatment has failed, German biotech Morphosys said, sending its shares down 9% in early Frankfurt trade on Tuesday. The clinical development process for its MOR106 antibody, which was jointly carried out by Switzerland’s Novartis, Belgo-Dutch biotech Galapagos NV and the German biotech was unlikely to meet its primary endpoint, Morphosys said. “The decision was based on a lack of efficacy and not on safety concerns,” Morphosys said in a statement. Galapagos and Morphosys announced their collaboration with the Swiss pharma giant in July 2018, saying the treatment would be aimed at curing atopic dermatitis, a condition that results in red and itchy skin, and potentially other conditions. “Together with our collaboration partners, we will explore the future strategy with MOR106,” Morphosys said. Reporting by Tassilo Hummel, editing by Rih
Show less
Read more
Impact Snapshot
Event Time:
MOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MOR alerts
High impacting MorphoSys AG - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MOR
News
- MorphoSys: Hold Rating Until The Novartis Deal Closes [Seeking Alpha]Seeking Alpha
- MorphoSys reports Q1 results [Seeking Alpha]Seeking Alpha
- European Stocks Steady as Philips Soars, Deutsche Bank Drops [BNN Bloomberg (Canada)]BNN Bloomberg
- MorphoSys AG Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- MorphoSys AG Reports First Quarter 2024 Financial ResultsBusiness Wire